Ann: Commencement of Larger Animal Studies for Lead Program, page-47

Having followed this company for the last ten years ( Only actively holding after CR since 13.5 cents ), there is really very little not to like.
The period after the CR was the usual consolidation in price after a turbulent 2020.

We had now two false starts in the share price, both stopped out by delays in the updates, whereas scientifically, I am very impressed. I see this company to be a multiple drug pipeline giant in about 3 to 5 years.

I agree with your comments about presentation, in his latest video CEO also was referring to
trippling current MC due to biotech investors coming on board, similar as mentioned by as shape therapeutics, taking the company to the next level.
We are next in line, our talks with biotech banking earlier this year in the US will have had things put in place and positive results of our trials on larger animals could well trigger those commitments.

Having lived much of my professional life in the US, I believe that US based biotech investment strategies will be transformative for the company.

It is fun to watch this stock getting ready at a snails pace, should soon accelerate a little.

all IMO